Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
1.62
-0.04 (-2.41%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.55 - 1.64
52 week 1.25 - 3.75
Open 1.58
Vol / Avg. 1.01M/463,768.00
Mkt cap 214.57M
P/E     -
Div/yield     -
EPS -0.28
Shares 129.18M
Beta 1.71
Inst. own 55%
Aug 4, 2016
Q2 2016 Curis Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
Curis Inc at Jefferies Healthcare Conference
May 17, 2016
Curis Inc Annual Shareholders Meeting
May 9, 2016
Q1 2016 Curis Inc Earnings Release
May 9, 2016
Q1 2016 Curis Inc Earnings Call - Webcast
Apr 7, 2016
Curis Inc at Jefferies Immuno-Oncology Summit
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -547.02% -748.64%
Operating margin -510.25% -716.91%
EBITD margin - -714.87%
Return on average assets -42.01% -74.86%
Return on average equity -62.88% -125.10%
Employees 44 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
James E. Dentzer Chief Financial Officer, Chief Administrative Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Senior Vice President, Chief Strategy Officer
Bio & Compensation  - Reuters
David Tuck M.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters